Cell and gene therapies are quickly reaching an inflection point, showing great promise for the future of patient care. At GE Healthcare’s Cell Therapy Technologies, we strive to be at the forefront of this revolution by providing the right combination of customized tools, analytics, and support, while helping to standardize and optimize scale-out manufacturing technologies. Together we hope to realize the promise of these revolutionary new medicines and bring them into mainstream clinical use.
Hypertrust patient data care provides unique blockchain-based solutions for secure handling of patient and other sensitive data.The first application is the patient-centered closed-loop supply and distributed data chain for autologous cell therapies. With hypertrust X-Chain we created a next-generation solution enabling a safe, efficient and transparent exchange of data across the entire process of autologous cell therapies – with far-reaching benefits for pharma companies and all other stakeholders in the supply and data chain.
Data-driven and highly-targeted immunotherapies are the future of the fight against cancer. IsoPlexis, develops novel solutions that are accelerating the revolution in immune and cell-based treatments of cancer. The Isolight, a next-generation analytics platform, profiles responses at the single-cell level enabling researchers to generate a precise functional patient signature to help predict and understand complex response to cancer immunotherapies.
Retrogenix provides a fast, accurate and effective solution for primary receptor identification and specificity screening of antibodies, protein ligands, CAR T cells, viruses and small molecules. Physiologically-relevant targets are identified by screening for interactions against the most comprehensive set of plasma membrane proteins available in the context of human cells. This specific sensitive technology is widely used by major global pharmaceutical companies to advance drug discovery and development, predominantly in biologics research.
Miltenyi Biotec’s mission is to improve scientific understanding and medical progress. By developing innovative products that address the processes that are necessary for the study of immuno-oncology we help researchers advance science in these key areas as well as help clinicians to make the concept of cellular therapy a reality.
Key Biologics provides biological products to the cell therapy industry worldwide. Non-mobilized and G-CSF mobilized MNC collections are performed under proprietary IRB-approved protocols. Three G-CSF schedules are available: 4day/10ug per kg/single collection, 5day/10ug per kg/single collection and 5day/5ug per kg/two collections. Key operates the Spectra, Optia and Amicus devices allowing customers to compare MNC product characteristics that could influence manufacturing of autologous or allogeneic cell-based therapies.
Fresenius Kabi is a leading global health care company that focuses on pharmaceuticals and medical devices used to care for critically and chronically ill patients. We bring over 60 years experience advancing the fields of cell collection and separation with expertise in closed-system processing. We recently launched Lovo, the only cell processing system that washes and concentrates white blood cells using filtration technology, specifically to serve the needs of the cellular therapies community.